vs
Pacira BioSciences, Inc.（PCRX）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是Pacira BioSciences, Inc.的1.7倍（$297.2M vs $177.4M），SHOE CARNIVAL INC净利率更高（4.9% vs 1.6%，领先3.3%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -3.2%），过去两年SHOE CARNIVAL INC的营收复合增速更高（3.0% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
PCRX vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.7倍
$177.4M
营收增速更快
PCRX
高出8.2%
-3.2%
净利率更高
SCVL
高出3.3%
1.6%
两年增速更快
SCVL
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $297.2M |
| 净利润 | $2.9M | $14.6M |
| 毛利率 | — | 37.6% |
| 营业利润率 | 3.9% | 6.3% |
| 净利率 | 1.6% | 4.9% |
| 营收同比 | 5.0% | -3.2% |
| 净利润同比 | — | -23.9% |
| 每股收益（稀释后） | $0.07 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXSCVL
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $297.2M | ||
| Q3 25 | $179.5M | $306.4M | ||
| Q2 25 | $181.1M | $277.7M | ||
| Q1 25 | $168.9M | $262.9M | ||
| Q4 24 | $187.3M | $306.9M | ||
| Q3 24 | $168.6M | $332.7M | ||
| Q2 24 | $178.0M | $300.4M |
净利润PCRXSCVL
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $14.6M | ||
| Q3 25 | $5.4M | $19.2M | ||
| Q2 25 | $-4.8M | $9.3M | ||
| Q1 25 | $4.8M | $14.7M | ||
| Q4 24 | — | $19.2M | ||
| Q3 24 | $-143.5M | $22.6M | ||
| Q2 24 | $18.9M | $17.3M |
毛利率PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 37.6% | ||
| Q3 25 | 80.9% | 38.8% | ||
| Q2 25 | 77.4% | 34.5% | ||
| Q1 25 | 79.7% | 34.9% | ||
| Q4 24 | 78.7% | 36.0% | ||
| Q3 24 | 76.9% | 36.1% | ||
| Q2 24 | 75.1% | 35.6% |
营业利润率PCRXSCVL
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 6.3% | ||
| Q3 25 | 3.5% | 8.2% | ||
| Q2 25 | 4.7% | 4.3% | ||
| Q1 25 | 1.2% | 5.3% | ||
| Q4 24 | 13.2% | 8.0% | ||
| Q3 24 | -82.8% | 9.0% | ||
| Q2 24 | 15.9% | 7.5% |
净利率PCRXSCVL
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 6.3% | ||
| Q2 25 | -2.7% | 3.4% | ||
| Q1 25 | 2.8% | 5.6% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -85.1% | 6.8% | ||
| Q2 24 | 10.6% | 5.8% |
每股收益（稀释后）PCRXSCVL
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.53 | ||
| Q3 25 | $0.12 | $0.70 | ||
| Q2 25 | $-0.11 | $0.34 | ||
| Q1 25 | $0.10 | $0.53 | ||
| Q4 24 | $0.38 | $0.70 | ||
| Q3 24 | $-3.11 | $0.82 | ||
| Q2 24 | $0.39 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $683.2M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXSCVL
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $107.7M | ||
| Q3 25 | $246.3M | $91.9M | ||
| Q2 25 | $445.9M | $93.0M | ||
| Q1 25 | $493.6M | $123.1M | ||
| Q4 24 | $484.6M | $91.1M | ||
| Q3 24 | $453.8M | $84.5M | ||
| Q2 24 | $404.2M | $69.5M |
总债务PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXSCVL
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $683.2M | ||
| Q3 25 | $727.2M | $670.7M | ||
| Q2 25 | $757.8M | $653.6M | ||
| Q1 25 | $798.5M | $649.0M | ||
| Q4 24 | $778.3M | $635.7M | ||
| Q3 24 | $749.6M | $618.5M | ||
| Q2 24 | $879.3M | $597.8M |
总资产PCRXSCVL
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B |
负债/权益比PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $33.6M |
| 自由现金流经营现金流 - 资本支出 | — | $19.7M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.7% |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | — | $35.1M |
8季度趋势，按日历期对齐
经营现金流PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $33.6M | ||
| Q3 25 | $60.8M | $13.3M | ||
| Q2 25 | $12.0M | $-9.6M | ||
| Q1 25 | $35.5M | $44.5M | ||
| Q4 24 | $33.1M | $17.3M | ||
| Q3 24 | $53.9M | $23.7M | ||
| Q2 24 | $53.2M | $17.1M |
自由现金流PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $19.7M | ||
| Q3 25 | $57.0M | $2.2M | ||
| Q2 25 | $9.3M | $-23.0M | ||
| Q1 25 | $26.9M | $36.2M | ||
| Q4 24 | $31.0M | $8.3M | ||
| Q3 24 | $49.8M | $18.2M | ||
| Q2 24 | $51.6M | $6.9M |
自由现金流率PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 6.6% | ||
| Q3 25 | 31.7% | 0.7% | ||
| Q2 25 | 5.1% | -8.3% | ||
| Q1 25 | 15.9% | 13.8% | ||
| Q4 24 | 16.6% | 2.7% | ||
| Q3 24 | 29.6% | 5.5% | ||
| Q2 24 | 29.0% | 2.3% |
资本支出强度PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.7% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 4.8% | ||
| Q1 25 | 5.1% | 3.2% | ||
| Q4 24 | 1.1% | 3.0% | ||
| Q3 24 | 2.4% | 1.7% | ||
| Q2 24 | 0.9% | 3.4% |
现金转化率PCRXSCVL
| Q1 26 | — | — | ||
| Q4 25 | — | 2.30× | ||
| Q3 25 | 11.20× | 0.69× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | 7.37× | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | 2.82× | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SCVL
暂无分部数据
